Etanercept should be the first line of treatment for patients who require anti-TNF therapy and are at a high risk of TB reactivation because anti-TNF monoclonal antibody medications (particularly adalimumab and infliximab) have a higher risk of TB reactivation than etanercept [28]. Here, TNF is linked to tuberculosis.